SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Trial Details

NCT ID
NCT06544265
Phase
PHASE1
Sponsor
Verismo Therapeutics
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • SynKIR-310
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Fairway, Kansas, United States|39.02223,-94.6319
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Adult 18 years of age and older.
  • Histologically confirmed diagnosis of B-NHL before enrollment.
  • Must have received prior CAR T or were unwilling/unable to receive prior CAR T.
  • Must have refractory or relapsed disease after receiving 2 prior lines of therapies.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →